Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase II trial studies giving capecitabine and vorinostat in
treating patients with head and neck cancer that has come back after previous treatment or
that has spread to other areas in the body. Drugs used in chemotherapy, such as capecitabine,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether giving capecitabine
together with vorinostat is more effective than capecitabine alone in treating patients with
cancer of the head and neck cancer.